Ivacaftor 75 MG Oral Tablet — RxCUI 2174388
RxNorm drug concept · Semantic clinical drug
RxCUI 2174388
Semantic clinical drug · SCD
● Current RxNorm concept 6 FDA products
6 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2174388
Official nameIvacaftor 75 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)51,949 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Ivacaftor: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Kalydeco doesn't cure cystic fibrosis, but it targets the root cause in people with certain gene mutations. It helps a faulty protein in your cells — called CFTR — work better by k...
- What exactly does Kalydeco do for cystic fibrosis — does it cure it?
- It really does matter what you take it with. Fat in food increases how much ivacaftor your body absorbs — by as much as 2.5 to 4 times. Taking it with just water means you're likel...
- Why does it have to be taken with food? Can I just take it with water?
🕸️ Concept Web — How Ivacaftor 75 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Ivacaftor 75 MG Oral Tablet
RxCUI 2174388 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Ivacaftor
1243041IN
-
Ivacaftor
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Ivacaftor Oral Tablet
1243045SCDF -
Ivacaftor Oral Product
1243043SCDG -
Ivacaftor Pill
1243044SCDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Ivacaftor Oral Tablet
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Ivacaftor 75 MG
1606867SCDC
-
Ivacaftor 75 MG
-
Packs 4
Fixed collections of drugs packaged and sold together, like dose packs.
-
{28 (ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack [Symdeko (50 MG / 75 MG; 75 MG)]
2174390BPCK -
{56 (elexacaftor 50 MG / ivacaftor 37.5 MG / tezacaftor 25 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack [Trikafta (50 MG / 37.5 MG / 25 MG; 75 MG)]
2557216BPCK -
{28 (ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack
2174389GPCK -
{56 (elexacaftor 50 MG / ivacaftor 37.5 MG / tezacaftor 25 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack
2557215GPCK
-
{28 (ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack [Symdeko (50 MG / 75 MG; 75 MG)]
Showing up to 8 concepts per family — 12 of 12 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
{28 (ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack
GPCK · 2174389 -
{56 (elexacaftor 50 MG / ivacaftor 37.5 MG / tezacaftor 25 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack
GPCK · 2557215 -
Ivacaftor 75 MG
SCDC · 1606867 -
Ivacaftor Oral Tablet
SCDF · 1243045 -
Ivacaftor Oral Product
SCDG · 1243043 -
Ivacaftor Pill
SCDG · 1243044
Brand-Name Concepts
-
{28 (ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack [Symdeko (50 MG / 75 MG; 75 MG)]
BPCK · 2174390 -
{56 (elexacaftor 50 MG / ivacaftor 37.5 MG / tezacaftor 25 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack [Trikafta (50 MG / 37.5 MG / 25 MG; 75 MG)]
BPCK · 2557216
📦 FDA Products & Package NDCs
6 products · 6 package NDCs
6 package NDCs map to RxCUI 2174388 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 51167-0106-02 | 4 BLISTER PACK in 1 CARTON (51167-106-02) / 1 KIT in 1 BLIS... | Trikafta | Vertex Pharmaceuticals Incorporated | 2021-06-08 |
| 51167-0113-01 | 1 KIT in 1 CARTON (51167-113-01) * 7 TABLET, FILM COATED i... | SYMDEKO | Vertex Pharmaceuticals Incorporated | 2019-06-21 |
| 51167-0331-01 | 4 BLISTER PACK in 1 CARTON (51167-331-01) / 1 KIT in 1 BLIS... | Trikafta | Vertex Pharmaceuticals Incorporated | 2019-10-21 |
| 51167-0445-01 | 4 PACKAGE in 1 CARTON (51167-445-01) / 1 KIT in 1 PACKAGE *... | Trikafta | Vertex Pharmaceuticals Incorporated | 2023-04-26 |
| 51167-0446-01 | 4 PACKAGE in 1 CARTON (51167-446-01) / 1 KIT in 1 PACKAGE *... | Trikafta | Vertex Pharmaceuticals Incorporated | 2023-04-26 |
| 51167-0661-01 | 1 KIT in 1 CARTON (51167-661-01) * 7 TABLET, FILM COATED i... | SYMDEKO | Vertex Pharmaceuticals Incorporated | 2018-02-12 |
Observed labelers:
Vertex Pharmaceuticals Incorporated (6)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.